HIV Guidelines. New Strategies.

Size: px
Start display at page:

Download "HIV Guidelines. New Strategies."

Transcription

1 HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid

2 HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention

3 HIV Guidelines WhentoStart. Whattostart. 3

4 EACS Guidelines, 2014: When to Start 4

5 IAS-USA Guidelines, 2014: When to Start 5

6 GeSIDAGuidelines, 2015: When to Start ART is recommended for all HIV infected patients. CD4 count <350 cells/µl (AI) CD4 count cells/µl (AII) CD4 count >500 cells/µl (BIII) 6

7 Temprano Trial: Overview Temprano ANRS Study Group. N Engl J Med. 2015;373:

8 Temprano Trial: Severe HIV morbidity Temprano ANRS Study Group. N Engl J Med. 2015;373:

9 Temprano Trial: Severe HIV morbidity Baseline CD4 500/mm 3 (n=849) Temprano ANRS Study Group. N Engl J Med. 2015;373:

10 Start: StudyDesign The INSIGHT START Study Group. N Engl J Med. 2015;373:

11 START: Primary Endpoint Type of event Nº de participantes Imm. ART Def. ART Serious AIDS Serious non-aids Total Cumulative Percent with an event Months The INSIGHT START Study Group. N Engl J Med. 2015;373:

12 DHHS Guidelines, 2015: When to Start Strongly recommended for all CD4 counts: CD4 count <350 cells/µl (AI) CD4 count cells/µl (AI) CD4 count >500 cells/µl (A1) 12

13 EACS Guidelines, 2014: What to Start 13

14 IAS-USA Guidelines, 2014: What to Start 14

15 DHHS Guidelines, April 2015: What to Start Recommended Regimens INSTI based PI based DTG/ABC/3TC* DTG + TDF/FTC EVG/COBI/TDF/FTC RAL + TDF/FTC DRV/r + TDF/FTC *Only for pts who are HLA-B*5701 negative. Only for pts with pre-art CrCl 70 ml/min. NNRTIs and ATV/r, previously classified as recommended, are now alternative regimens DHHS Guidelines. April 2015.

16 Preferred GeSIDAGuidelines, 2015: What to Start Regimens that have shown superior efficacy to their comparators in randomized clinical trials and that present a low risk of pharmacological interactions. They can be given to most patients. ABC/3TC + DTG TDF/FTC + DTG TDF/FTC + RAL Alternatives Regimens that have been inferior to the preferred regimens in randomized clinical trials or that have potential disadvantages or restrictions in their indications. They may be preferred options in some patients. 16

17 New Strategies. The End of AIDS? diagnose and treat prevention cure

18 HIV Prevention: Opportunities for biomedical interventions YEARS HOURS 36 HOURS YEARS Prior to exposure Exposure (pre-coital/coital) Exposure (post-coital) After infection Male circumcision Oral pre exposure prophylaxis (daily PrEP) Topical PrEP (daily gels or intra-vaginal rings (microbicides) Preventive Vaccines Oral pre exposure prophylaxis (intermittent PrEP) Coitally dependent topical PrEP (microbicides) Oral post exposure prophylaxis (PEP) Anti-retroviral therapy Immediate treatment of positive partners in discordant couples Treatment for prevention in all who test positive for HIV (T4P)

19 TasP: HIV prevention pyramid Treatment as prevention Vaccine PrEP PMTCT STI treatment Male circumcision Microbicides Testing & counselling Education Drug & alcohol treatment Condoms Harm reduction Blood screening Fauci A. IAC Abstract MOPL

20 Higher incidences of heterosexual transmissions with unsuppressed viral loads Mean (+SE) rate of heterosexual transmission of HIV-1 among 415 couples, according to the sex and the serum HIV-1 RNA level of the HIV-positive partner Transmission rate per 100 Person-years All subjects Male-to-Female Transmission Female-to-Male Transmission 0 Quinn TC et al. N Engl J Med 2000;342: HIV-1 RNA (copies/ml) 20

21 Spain (Madrid) serodiscordantcouples Evidence supporting TasP as a strategy to achieve reductions in HIV transmission In serodiscordant couples with the HIV-positive partner not on ART, 9.2% of HIV-negative partners had HIV seroprevalence at enrolment, versus 0% of couples with the HIV-positive partner on ART During follow-up: Serodiscordant couple characteristics HIV-positive partner not on ARV Practicing unprotected sex (N=341) Using a condom (N=294) Estimated total acts of intercourse 11,000 42,000 Seroconversions HIV-positive partner on ARV Practicing unprotected sex (N=144) 7,000 0 Del Romero J et al. BMJ 2010;340:c

22 HIV sexual transmissibility meta-analysis: No transmission on ART below 400 copies/ml Attia S, et al.aids 2009 Jul 17;23(11):

23 Partner Cohort Study: HIV Transmission Risk Despite Condomless Sex International Observational Cohort Study of sero-discordant couples Analyzed transmission risk from HIV+ on ARVs with undetectable viral load from condomless sexual acts no PEP nor PREP used in HIV- Analysis of transmissions linked to partner thru phylogenetic analysis Anal sex Ten-year risk of HIV Transmission: % Receptive Anal, with 0-3.9% or without overall 0-9.2% for condomless anal sex Observed Transmissions 95% CI for 100 couple years Overall % ejaculation % Rodger A, et al. 21st CROI; Boston, MA; March 3-6, Abst. 153LB.

24 Treatment as prevention TasP Internationally, HIV-positive population trends are declining 1-4 For an individual, it has been demonstrated that the rate ratio of incidence of HIV infection is more favourable with the administration of ART 5 The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy 6 Cumulative probability No. at risk Immediate Delayed 0 HPTN 052: Linked HIV transmission Years since randomisation Delayed Immediate Wood E, et al. BMJ 2009;338:b1649; 2. Montaner JSG, et al. Lancet 2010;376:532-9; 3. Das M, et al. PLoS ONE 2010;5:e11068; 4. Henard S, et al. J Acquir Immune Defic Syndr 2012;61: ; 5. Anglemyer A, et al. Cochrane Database Syst Rev 2011;(8):CD009153; 6. Cohen MS, et al. N Engl J Med 2011;365:

25 Community Viral Load Mirrors Reduced Rate of New HIV Cases in San Francisco Retrospective analysis of relationship between community viral load (mean of summed individual HIV-1 RNA results per yr) and new HIV diagnoses Mean Community Viral Load (copies/ml) 30,000 25,000 20,000 15,000 10, P =.005 for association* 798 Das-Douglas M, et al. CROI Abstract 33. Mean CVL Newly diagnosed and reported HIV cases *Data insufficient to prove significant association with Yrreduced HIV incidence Number of Newly Diagnosed HIV Cases

26 Reduction in New HIV Diagnoses in BC: Testing, HAART, and Community VL Period of declining new HIV diagnoses in BC coincident with increased HIV testing rates, increased uptake of antiretroviral therapy, and decrease in community viral load ( ) Decline in new HIV diagnoses despite increases in syphilis, gonorrhea, chlamydia Patients (n) 12,000 10, New HIV+ diagnoses (all) Censored at the time of death or move New HIV+ Diagnoses (n) HIV-1 RNA, copies/ml < ,000-49,999 50, Montaner J, et al. CROI Abstract 88LB.

27 Potential cost savings of different ART initiation points (South Africa) US$ (billions) US$7.2 billion * US$17.3 billion * US$28.7 billion * Treatment initiation CD4 <200 CD4 <350 CD4 <500 All CD * Cumulative potential cost savings from Granich R et al. PLoS ONE 2012; 7:e

28 HIV Guidelines. New Strategies. Outline HIV Guidelines are evolving Earlier initiation of ART: All HIV-infected patients regardless CD4 counts to decrease morbidity and mortality, and to prevent transmission (A1) More limited preferred options: evidence supporting integrase inhibitors-based regimens New strategies Administration of ART to infected patients is at present the most efficacious strategy to prevent HIV transmission

29 Hospital Ramón y Cajal Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Thank Universidad de Alcalá de You Henares

The use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART?

The use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART? World Health Organization brief on antiretroviral treatment (ART) in HIV and TB prevention. Date: January 2011 This brief is intended as an introduction for WHO staff to the HIV and TB preventive benefit

More information

HPTN 073: Black MSM Open-Label PrEP Demonstration Project

HPTN 073: Black MSM Open-Label PrEP Demonstration Project HPTN 073: Black MSM Open-Label PrEP Demonstration Project Overview HIV Epidemiology in the U.S. Overview of PrEP Overview of HPTN HPTN 061 HPTN 073 ARV Drug Resistance Conclusions Questions and Answers

More information

The Botswana Combination Prevention Project (BCPP)

The Botswana Combination Prevention Project (BCPP) The Botswana Combination Prevention Project (BCPP) The Next Phase of HIV Prevention in Botswana A collaboration between MoH CDC-Botswana, HSPH-BHP Presenter: M.J. Makhema NAC 4 th September 2012 Mashi

More information

The New Era of HIV Treatment as Prevention: Will Behavior Trump Biology? Seth C. Kalichman University of Connecticut

The New Era of HIV Treatment as Prevention: Will Behavior Trump Biology? Seth C. Kalichman University of Connecticut The New Era of HIV Treatment as Prevention: Will Behavior Trump Biology? Seth C. Kalichman University of Connecticut Getting to Zero Relies on HIV Treatment as Prevention Microbicides Diaphragm Female

More information

Integrating HIV Prevention and Care into Primary Care in Community Health Centers

Integrating HIV Prevention and Care into Primary Care in Community Health Centers Integrating HIV Prevention and Care into Primary Care in Community Health Centers March 14, 2013 Harvey J. Makadon MD Director of Professional Education The National LGBT Health Education Center The Fenway

More information

Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers

Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers James Wilton Coordinator, Biomedical Science of HIV Prevention

More information

HIV viral load, HIV treatment and sexual HIV transmission

HIV viral load, HIV treatment and sexual HIV transmission FACTSHEET HIV viral load, HIV treatment and sexual HIV transmission Summary HIV viral load is the amount of HIV (or number of virus) in the bodily fluids of someone living with HIV. It is measured in the

More information

Introducing the PrEP Package for Enhanced HIV Prevention: A Practical Guide for Clinicians

Introducing the PrEP Package for Enhanced HIV Prevention: A Practical Guide for Clinicians WE09 Handout Introducing the PrEP Package for Enhanced HIV Prevention: A Practical Guide for Clinicians Although advances in treatment have improved the quality and length of life for individuals infected

More information

Wafaa El-Sadr, MD, MPH ICAP, Columbia University. HIV Prevention: A Global Priority

Wafaa El-Sadr, MD, MPH ICAP, Columbia University. HIV Prevention: A Global Priority Wafaa El-Sadr, MD, MPH ICAP, Columbia University HIV Prevention: A Global Priority Millions Global Number of People Living with HIV, by year 35 30 25 20 15 10 5 0 1990 1991 1992 1993 1994 1995 1996 1997

More information

Will a Pill a Day Keep HIV Away?

Will a Pill a Day Keep HIV Away? Will a Pill a Day Keep HIV Away? Sybil Hosek, PhD Department Of Psychiatry Stroger Hospital Of Cook County YES! BUT ONLY IF YOU TAKE IT What is PrEP? PrEP stands for Pre-Exposure Prophylaxis Prophylaxis

More information

Will We End the HIV Epidemic?

Will We End the HIV Epidemic? Will We End the HIV Epidemic? The Impact of HIV Treatment on HIV Prevention and Implications for the 2010 Replenishment of the Global Fund to Fight AIDS, TB and Malaria Photo: UNAIDS/A.Gutman March 2010

More information

HIV Treatment-as-Prevention: A Public Health Primer

HIV Treatment-as-Prevention: A Public Health Primer HIV Treatment-as-Prevention: A Public Health Primer Presented by Dr. Doug Sider, Dr. Kate Bingham Developed by Dr. Doug Sider, Dr. Kate Bingham, Dr. Liane Macdonald PHO Rounds - 26 March, 2013 DEFINING

More information

Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: 2015 Update

Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: 2015 Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: 2015 Update Brian R. Wood, MD (bwood2@uw.edu) Harborview Medical Center University of Washington June 26,

More information

ROUTINE HIV SCREENING: A REVIEW OF THE EVIDENCE FROM 2007 TO 2010 SEPTEMBER 2010

ROUTINE HIV SCREENING: A REVIEW OF THE EVIDENCE FROM 2007 TO 2010 SEPTEMBER 2010 ROUTINE HIV SCREENING: A REVIEW OF THE EVIDENCE FROM 2007 TO 2010 SEPTEMBER 2010 Since the USPSTF conducted its focused update of the evidence on routine HIV screening in 2007: earlier initiation of antiretroviral

More information

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline Background... 2 Screening Recommendations...2 HIV Test Ordering and Consent... 2 Indications for Periodic HIV

More information

Multipurpose prevention technologies and their potential interaction with vaccines. Robin Shattock

Multipurpose prevention technologies and their potential interaction with vaccines. Robin Shattock Multipurpose prevention technologies and their potential interaction with vaccines Robin Shattock Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/coital)

More information

1. This statement refers to the use of antiretroviral therapy (ART) by HIV-positive individuals to reduce the risk of transmission of HIV.

1. This statement refers to the use of antiretroviral therapy (ART) by HIV-positive individuals to reduce the risk of transmission of HIV. EAGA Page 1 of 6 Position statement on the use of antiretroviral therapy to reduce HIV transmission. September 2014. The British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA) Members

More information

Health System Concerns Related to TasP and Most At Risk Populations. Example from the United Kingdom Impact of TasP on the MSM epidemic

Health System Concerns Related to TasP and Most At Risk Populations. Example from the United Kingdom Impact of TasP on the MSM epidemic Health System Concerns Related to TasP and Most At Risk Populations Example from the United Kingdom Impact of TasP on the MSM epidemic Dr Valerie Delpech Context Population of 60.5 million NHS provides

More information

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline Background... 2 Screening... 2 Recommendations... 2 Ordering and consent... 2 Indications for Periodic HIV Screening...

More information

The Odyssey of the ANRS Ipergay Trial: On Demand PrEP for High Risk MSM

The Odyssey of the ANRS Ipergay Trial: On Demand PrEP for High Risk MSM The Odyssey of the ANRS Ipergay Trial: On Demand PrEP for High Risk MSM Jean-Michel Molina, MD and the ANRS Ipergay study group University of Paris Diderot, Paris 7 and Saint-Louis Hospital in Paris New

More information

New paths of HIV prevention

New paths of HIV prevention New paths of HIV prevention Joe E. McAdams Director of HIV Training Service HIV Connection Community Partner Advocate Austin PrEP Access Project Some topics we will cover today: Pre exposure Prophylaxis

More information

Ipergay: On-Demand PrEP Study Design

Ipergay: On-Demand PrEP Study Design On Demand PrEP with Oral in MSM Results of the ANRS Ipergay Trial Molina JM, Capitant C, SpireB, Pialoux G, Chidiac C, Charreau I, Tremblay C, Meyer L, Delfraissy JF, and the ANRS Ipergay Study Group Hospital

More information

The Basics of Drug Resistance:

The Basics of Drug Resistance: CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?

More information

HIV Prevention Research Tools

HIV Prevention Research Tools No Participant Guide page. Welcome participants to the course. Tell participants to sit down anywhere they will be comfortable. Thank participants for coming to the workshop. Remind participants that the

More information

TECHNICAL REPORT. Evaluating HIV treatment as prevention in the European context. www.ecdc.europa.eu

TECHNICAL REPORT. Evaluating HIV treatment as prevention in the European context. www.ecdc.europa.eu TECHNICAL REPORT Evaluating HIV treatment as prevention in the European context www.ecdc.europa.eu ECDC TECHNICAL REPORT Evaluating HIV treatment as prevention in the European context This report was commissioned

More information

PrEP: Discussion Paper

PrEP: Discussion Paper PrEP: Discussion Paper On 25 August 2015, HIV Scotland will bring together key stakeholders to discuss the current and future use of PrEP in Scotland. This discussion paper has been created in advance

More information

Frequently Asked Questions about Pre-exposure Prophylaxis (PrEP) August, 2015

Frequently Asked Questions about Pre-exposure Prophylaxis (PrEP) August, 2015 Frequently Asked Questions about Pre-exposure Prophylaxis (PrEP) August, 2015 About this Document This document has been developed to respond to questions that might arise during discussions on PrEP in

More information

Contextualizing PrEP s Role in Controlling HIV

Contextualizing PrEP s Role in Controlling HIV Contextualizing PrEP s Role in Controlling HIV Controlling the HIV Epidemic with ARVs 1-2 October 2015 David Burns Prevention Sciences Program Division of AIDS, NIAID, NIH Contextualizing PrEP Controlling

More information

Clinical Infectious Diseases Advance Access published September 1, 2015

Clinical Infectious Diseases Advance Access published September 1, 2015 Clinical Infectious Diseases Advance Access published September 1, 2015 1 No New HIV Infections with Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting Jonathan E. Volk 1, Julia

More information

HIV/AIDS Prevention and Care

HIV/AIDS Prevention and Care HIV/AIDS Prevention and Care Nancy S. Padian, PhD, MPH Professor, Obstetrics, Gynecology & Reproductive Sciences Associate Director for Research, Global Health Sciences and AIDS Research Institute: University

More information

ART and HIV: Treatment as Prevention Myron S. Cohen, MD University of North Carolina

ART and HIV: Treatment as Prevention Myron S. Cohen, MD University of North Carolina ART and HIV: Treatment as Prevention Myron S. Cohen, MD University of North Carolina Uses of ART for HIV Prevention Cohen et al. Annals Int Med, 2007 Pre exposure prophylaxis: 21,000 subjects in PrEP trials

More information

Simplifying Antiretroviral Therapy: The Way Forward

Simplifying Antiretroviral Therapy: The Way Forward Simplifying Antiretroviral Therapy: The Way Forward Calvin Cohen, MD, MSc Clinical Instructor Harvard Medical School Research Director Harvard Vanguard Medical Associates Director of Research Community

More information

Glossary of HIV/AIDS-Related Terms

Glossary of HIV/AIDS-Related Terms Chapter 48 Glossary of HIV/AIDS-Related Terms acquired immunodeficiency syndrome (AIDS): A disease of the body s immune system caused by the human immunodeficiency virus (HIV). AIDS is characterized by

More information

IMPLEMENTING CLINICAL RECOMMENDATIONS: ART STRATEGIES, TOOLS, AND HEALTHY SYSTEMS/SERVICE DELIVERY RECOMMENDATIONS 11-14: ADHERENCE

IMPLEMENTING CLINICAL RECOMMENDATIONS: ART STRATEGIES, TOOLS, AND HEALTHY SYSTEMS/SERVICE DELIVERY RECOMMENDATIONS 11-14: ADHERENCE IMPLEMENTING CLINICAL RECOMMENDATIONS: ART STRATEGIES, TOOLS, AND HEALTHY SYSTEMS/SERVICE DELIVERY RECOMMENDATIONS 11-14: ADHERENCE John G. Bartlett Johns Hopkins University School of Medicine May 2012

More information

Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis. John Ferguson, UPNG 2012

Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis. John Ferguson, UPNG 2012 Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis John Ferguson, UPNG 2012 Outline Epidemiology Making the diagnosis / contact tracing Antiretroviral

More information

The strategic use of antiretrovirals to help end the HIV epidemic

The strategic use of antiretrovirals to help end the HIV epidemic The strategic use of antiretrovirals to help end the HIV epidemic 2 WHO Department of HIV/AIDS The strategic use of antiretrovirals to help end the HIV epidemic WHO Library Cataloguing-in-Publication Data

More information

INTERVENTION TO PREVENT HIV/AIDS. Roger Detels

INTERVENTION TO PREVENT HIV/AIDS. Roger Detels INTERVENTION TO PREVENT HIV/AIDS Roger Detels NEED TO RETURN TO PUBLIC HEALTH PRINCIPLES Discard concept of exceptionalism Primary responsibility to protect the uninfected Promote testing Prevent transmission

More information

HIV and Other Sexually Transmitted Infections. Emily J. Erbelding, MD, MPH Johns Hopkins University

HIV and Other Sexually Transmitted Infections. Emily J. Erbelding, MD, MPH Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Pre-exposure prophylaxis (PrEP)

Pre-exposure prophylaxis (PrEP) FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.

More information

A summary of the evidence, questions and the trials addressing TasP? Sarah Fidler Imperial College London

A summary of the evidence, questions and the trials addressing TasP? Sarah Fidler Imperial College London A summary of the evidence, questions and the trials addressing TasP? Sarah Fidler Imperial College London Overview What is the evidence Is a trial needed What are the current trials PopART HPTN071 ART

More information

Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013

Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013 Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013 On July 16, 2012, the Food and Drug Administration (FDA) approved

More information

Small Talks ABOUT. Safer Sexual Behaviors. How health care providers can help patients living with HIV adopt safer sexual behaviors

Small Talks ABOUT. Safer Sexual Behaviors. How health care providers can help patients living with HIV adopt safer sexual behaviors Small Talks ABOUT Safer Sexual Behaviors How health care providers can help patients living with HIV adopt safer sexual behaviors 1 Introduction Safer Sexual Behaviors A growing number of people are living

More information

HIV New Diagnoses, Treatment and Care in the UK 2015 report

HIV New Diagnoses, Treatment and Care in the UK 2015 report HIV New Diagnoses, Treatment and Care in the UK 2015 report About Public Health England Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities.

More information

STOP HIV TB: Special Populations, The Vancouver Experience

STOP HIV TB: Special Populations, The Vancouver Experience STOP HIV TB: Special Populations, The Vancouver Experience Rolando Barrios, MD Assistant Director BC Centre for Excellence in HIV/AIDS Senior Medical Director Vancouver Community Health Services, Vancouver

More information

SCIENTIFIC RESEARCH ON THE RISK OF THE SEXUAL TRANSMISSION OF HIV INFECTION AND ON HIV AS A CHRONIC MANAGEABLE INFECTION

SCIENTIFIC RESEARCH ON THE RISK OF THE SEXUAL TRANSMISSION OF HIV INFECTION AND ON HIV AS A CHRONIC MANAGEABLE INFECTION SCIENTIFIC RESEARCH ON THE RISK OF THE SEXUAL TRANSMISSION OF HIV INFECTION AND ON HIV AS A CHRONIC MANAGEABLE INFECTION Update of section 3, Scientific research on the risk of the sexual transmission

More information

Biological Prevention of HIV Transmission

Biological Prevention of HIV Transmission Biological Prevention of HIV Transmission Zubairi Djoerban and Samsuridjal Djauzi Faculty of Medicine University of Indonesia Contents o Current situation of HIV/AIDS worldwide. o Prevention of HIV transmission.

More information

PROUD. HIV PrEP PREVENTION STRATEGY CURRENT EVIDENCE FOR HIV PrEP (based on evidence available as of October 2014)... 4

PROUD. HIV PrEP PREVENTION STRATEGY CURRENT EVIDENCE FOR HIV PrEP (based on evidence available as of October 2014)... 4 PROUD PROUD Study Key Messages, Q&A and further HIV PrEP trial information For details of the study results see the PROUD Results Key Messages and Q&A (v2.0, 10 th December 2015) The following key messages

More information

Q and A for PARTNER Studies: Interim analysis results presented at CROI 2014. CROI presentation can be found at www.chip.dk

Q and A for PARTNER Studies: Interim analysis results presented at CROI 2014. CROI presentation can be found at www.chip.dk Q and A for PARTNER Studies: Interim analysis results presented at CROI 2014 STATUS: Results embargoed until 4 March 2014, 18:30 Central European Time (CET). CROI presentation can be found at www.chip.dk

More information

Sandro Vento. Department of Internal Medicine, Faculty of Medicine, University of Botswana

Sandro Vento. Department of Internal Medicine, Faculty of Medicine, University of Botswana Sandro Vento Department of Internal Medicine, Faculty of Medicine, University of Botswana Out of 34 million people currently infected with HIV/AIDS, over 90% live in low and middle income countries Although

More information

Q and A for PARTNER Studies:

Q and A for PARTNER Studies: General Q and A s Q and A for PARTNER Studies: What is the 1 st phase PARTNER study? The PARTNER study focuses on the risk of sexual HIV transmission when an HIV positive person is on treatment. The study

More information

TREAT EARLY TEST MORE STAY SAFE ENDING HIV

TREAT EARLY TEST MORE STAY SAFE ENDING HIV TREAT EARLY TEST MORE STAY SAFE ENDING HIV IS IT TRUE... that if a HIV positive partner is on treatment and has an undetectable viral load then there is almost no risk of HIV transmission in anal sex between

More information

SCIENTIFIC RESEARCH ON THE RISK OF THE SEXUAL TRANSMISSION OF HIV INFECTION AND ON HIV AS A CHRONIC MANAGEABLE INFECTION

SCIENTIFIC RESEARCH ON THE RISK OF THE SEXUAL TRANSMISSION OF HIV INFECTION AND ON HIV AS A CHRONIC MANAGEABLE INFECTION SCIENTIFIC RESEARCH ON THE RISK OF THE SEXUAL TRANSMISSION OF HIV INFECTION AND ON HIV AS A CHRONIC MANAGEABLE INFECTION Update of section 3, Scientific research on the risk of the sexual transmission

More information

Who Might Benefit from PrEP? Individual-Level Assessments

Who Might Benefit from PrEP? Individual-Level Assessments Webcast 2.2 Who Might Benefit from PrEP? Individual-Level Assessments P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S I O

More information

Rakai Health Sciences Program. Trial of male circumcision: safety in HIV+ men and effects in women and the community

Rakai Health Sciences Program. Trial of male circumcision: safety in HIV+ men and effects in women and the community Rakai Health Sciences Program Trial of male circumcision: safety in HIV+ men and effects in women and the community Funded: Bill and Melinda Gates Foundation Why include HIV+ men? Safety of circumcision

More information

WHO 2013 ARV Guidelines Launch Critical issues for Adults with HIV: Presentation of Systematic reviews and Main recommendations

WHO 2013 ARV Guidelines Launch Critical issues for Adults with HIV: Presentation of Systematic reviews and Main recommendations WHO 2013 ARV Guidelines Launch Critical issues for Adults with HIV: Presentation of Systematic reviews and Main recommendations Dr. Meg Doherty, WHO, Geneva Coordinator Treatment and Care Objectives of

More information

Update on Antiretroviral Treatment Guidelines 2015

Update on Antiretroviral Treatment Guidelines 2015 Update on Antiretroviral Treatment Guidelines 2015 Rajesh T. Gandhi, MD Disclosures: Educational grants to my institution from EBSCO, Gilead and Roche km Learning Objectives Identify recent changes in

More information

Gay Community Periodic Survey: Melbourne 2016

Gay Community Periodic Survey: Melbourne 2016 Gay Community Periodic Survey: Melbourne 06 Never Stand Still Art Social Sciences Centre for Social Research in Health Evelyn Lee Limin Mao Tex McKenzie Colin Batrouney Michael West Garrett Prestage Iryna

More information

Background Plasma viral load is a single best predictor of progression to AIDS and death.

Background Plasma viral load is a single best predictor of progression to AIDS and death. ABSTRACT # 1 Virological and immunological response to treatment of naïve HIV-1 positive patients with viral load >500,000 copies/ml: do we need personalized treatment for this class of patients? Gaetana

More information

CHAPTER 5 HOMOSEXUAL MEN IN SAN FRANCISCO : ESTIMATION OF PARAMETERS AND INCIDENCES

CHAPTER 5 HOMOSEXUAL MEN IN SAN FRANCISCO : ESTIMATION OF PARAMETERS AND INCIDENCES CHAPTER 5 HOMOSEXUAL MEN IN SAN FRANCISCO : ESTIMATION OF PARAMETERS AND INCIDENCES San Francisco (SF) has been chosen as the site for modeling HIV transmission in homosexual men because very good data

More information

The Future in HIV treatment in South Africa. Dr Francesca Conradie President of the Southern African HIV Clinicians Society

The Future in HIV treatment in South Africa. Dr Francesca Conradie President of the Southern African HIV Clinicians Society The Future in HIV treatment in South Africa Dr Francesca Conradie President of the Southern African HIV Clinicians Society The big picture Test and Treat The patient level New compounds New Formulations

More information

Epidemiology of HIV in NSW residents newly diagnosed with HIV infection up to 31 December 2013

Epidemiology of HIV in NSW residents newly diagnosed with HIV infection up to 31 December 2013 Epidemiology of HIV in NSW residents newly diagnosed with HIV infection up to December 0 Sections Page Summary Time trend in the HIV epidemic in NSW 4 Demographics of NSW residents newly diagnosed with

More information

Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort

Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort Gaetana Sterrantino Azienda Ospedaliero-Universitaria Careggi Infectious diseases, Florence, Italy Background

More information

Is treatment-as-prevention the new game-changer? Economic evaluation of HIV combination prevention

Is treatment-as-prevention the new game-changer? Economic evaluation of HIV combination prevention Is treatment-as-prevention the new game-changer? Economic evaluation of HIV combination prevention Till Bärnighausen 1,2, David E. Bloom 1, Salal Humair 1,3 1 Department of Global Health and Population,

More information

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission

More information

Issues in Perinatally HIV Infected Adolescents. Gloria P Heresi, MD Professor of Pediatrics UTHealth, Houston

Issues in Perinatally HIV Infected Adolescents. Gloria P Heresi, MD Professor of Pediatrics UTHealth, Houston Issues in Perinatally HIV Infected Adolescents Gloria P Heresi, MD Professor of Pediatrics UTHealth, Houston Perinatally HIV Infected Adolescents Who are they? How many? Issues of special impact MTCT Race

More information

Measure #338 (NQF 2082): HIV Viral Load Suppression -- National Quality Strategy Domain:Effective Clinical Care

Measure #338 (NQF 2082): HIV Viral Load Suppression -- National Quality Strategy Domain:Effective Clinical Care Measure #338 (NQF 2082): HIV Viral Load Suppression -- National Quality Strategy Domain:Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: The

More information

New challenges and new opportunities for HIV patients in 2009

New challenges and new opportunities for HIV patients in 2009 New challenges and new opportunities for HIV patients in 2009 New treatments New health concerns New families How they work New drugs: New Classes Old Classes Patient example AMU experience New Classes

More information

Slide 1. Antiretroviral Drugs in the Treatment and Prevention of HIV Infection

Slide 1. Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Noga Shalev MD MID 2009 Slide 1. Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Slide 2. Uses of Antiretroviral Agents: Antiretroviral agents (ART) have revolutionized the treatment

More information

Biomedical Interventions to Prevent HIV Infection

Biomedical Interventions to Prevent HIV Infection Biomedical Interventions to Prevent HIV Infection What works, what doesn t, and where do we go next? Ronald Gray Johns Hopkins University How do we develop and test the efficacy of a preventive intervention?

More information

Pre-exposure prophylaxis for men who have sex with men: A systematic review

Pre-exposure prophylaxis for men who have sex with men: A systematic review Pre-exposure prophylaxis for men who have sex with men: A systematic review Authors: Caitlin Kennedy and Virginia Fonner (Johns Hopkins Bloomberg School of Public Health, Department of International Health,

More information

In the wake of the 13th international

In the wake of the 13th international STDs, Viral Load, Circumcision, and the Transmission of HIV Thomas C. Quinn, md Professor of Medicine, International Health, Molecular Biology and Immunology Johns Hopkins University Summary by Tim Horn

More information

HIV Vaccine Research Up dates

HIV Vaccine Research Up dates HIV Vaccine Research Up dates Prof. Omu Anzala KAVI Department of Medical Microbiology University of Nairobi Vaccines Mechanism of Action Exposure Infection Disease Death Recovery HIV Vaccine After about

More information

Additional biomedical technologies and new understandings of existing technologies have created a promising new landscape for HIV prevention.

Additional biomedical technologies and new understandings of existing technologies have created a promising new landscape for HIV prevention. What is safe sex? The HIV prevention landscape has changed considerably in recent years. Condoms, used together with lubricant, remain the most effective barrier against the transmission of HIV, though

More information

HIV Drug resistanceimplications

HIV Drug resistanceimplications HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:

More information

Preventing Mother to Child Transmission (PMTCT) in South Africa

Preventing Mother to Child Transmission (PMTCT) in South Africa Preventing Mother to Child Transmission (PMTCT) in South Africa Deborah Jones, PhD; Stephen Weiss, PhD, MPH; Olga Villar-Loubet, PsyD; Szonja Vamos, MA; Ryan Cook, BA Karl Peltzer, PhD; Elisa Shikwane,

More information

Updated HIV Treatment Guidelines 2014

Updated HIV Treatment Guidelines 2014 NORTHWEST AIDS EDUCATION AND TRAINING CENTER Updated HIV Treatment Guidelines 2014 Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, NW AETC ECHO Last Updated:

More information

Engagement and Retention in HIV Care: A Work in Progress

Engagement and Retention in HIV Care: A Work in Progress Engagement and Retention in HIV Care: A Work in Progress Kenneth Mayer, MD Fenway Health Beth Israel Deaconess Medical Center Harvard Medical School ACTHIV May 12 th, 2012 Learning Objectives Upon completion

More information

HIV Prevention in Pregnancy

HIV Prevention in Pregnancy HIV Prevention in Pregnancy Cumulative incidence: 3.8 per 100 person-years (95%CI: 3.3 6.1) In comparison: Key populations incidence of 2.7-6.1 per 100 person-years Drake, PLoS Med 2014 Acute HIV infection

More information

HIV Update and Clinical Cases

HIV Update and Clinical Cases HIV Update and Clinical Cases Todd Ellerin, MD Infectious Diseases South Shore Hospital Brigham and Women s Hospital Harvard Medical School todd_ellerin_md@sshosp.org U.S. Preventive Services Task Force

More information

PrEP uptake among cisgender women at an urban, community-based STI clinic

PrEP uptake among cisgender women at an urban, community-based STI clinic PrEP uptake among cisgender women at an urban, community-based STI clinic Oni J. Blackstock MD MHS, Viraj V. Patel MD MPH, Uri Felsen MD MPH, Cedric Bien MD & Sachin Jain MD MPH 11 th International Conference

More information

Consolidated guidelines on the use of antiretroviral drugs for treating

Consolidated guidelines on the use of antiretroviral drugs for treating TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO

More information

Counselling Discordant Couples on HIV sexual transmission risk

Counselling Discordant Couples on HIV sexual transmission risk Counselling Discordant Couples on HIV sexual transmission risk February 27 th 2015 Mona Loutfy, MD, FRCPC, MPH Infectious Diseases Specialist & Clinical Researcher Women s College Research Institute, Women

More information

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)

More information

Aktuell HIV-forskning 2014-05-06

Aktuell HIV-forskning 2014-05-06 Aktuell HIV-forskning 2014-05-06 Alexey Kashpersky Aktuell HIV-forskning Bot Smittsamhet Nya läkemedel HIV och åldrande Etc HPTN 052 Prevention Conclusion Early ART that suppresses viral replication led

More information

Pre-exposure Prophylaxis (PrEP) for Health Care Providers

Pre-exposure Prophylaxis (PrEP) for Health Care Providers Pre-exposure Prophylaxis (PrEP) for Health Care Providers Introduction: Biomedical Revolution in HIV Prevention Treatment as Prevention Recent dramatic advances in HIV treatment have led the CDC to declare

More information

Protocol for the systematic review of virological outcomes after 12 Months of antiretroviral therapy in low and middle income countries

Protocol for the systematic review of virological outcomes after 12 Months of antiretroviral therapy in low and middle income countries Protocol for the systematic review of virological outcomes after 12 Months of antiretroviral therapy in low and middle income countries 1. Authors James H. McMahon Alfred Hospital, Melbourne, Australia

More information

TRUVADA - ARV PILL TO PREVENT HIV-1

TRUVADA - ARV PILL TO PREVENT HIV-1 TRUVADA - ARV PILL TO PREVENT HIV-1 In recent weeks there have been much talk and debate about the oral ARV drug Truvada. The purpose of this article is to clarify and explain different aspects about the

More information

Frequently Asked Questions (FAQs)

Frequently Asked Questions (FAQs) Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing

More information

Providing Optimal Care for Your MSM Patients

Providing Optimal Care for Your MSM Patients Providing Optimal Care for Your MSM Patients Medical providers have a critical role to play in improving the health outcomes of Black and Latino men who have sex with men (BLMSM). Studies reinforce the

More information

Best of en Infectiologie Infection par le VIH/SIDA

Best of en Infectiologie Infection par le VIH/SIDA Best of en Infectiologie Infection par le VIH/SIDA Jean-Michel Molina Université de Paris Diderot Hôpital Saint-Louis INSERM U941, Paris 17 es JNI, Lille, du 7 au 9 juin 2016 1 Déclaration d intérêts de

More information

A Summary of the National HIV/AIDS Strategy

A Summary of the National HIV/AIDS Strategy A Summary of the National HIV/AIDS Strategy July 2010 reported by 1375 Mission Street San Francisco CA 94103 July 2010 Vision of the Strategy: The US will become a place where new HIV infections are rare

More information

A Gay Men s Health Service Audit of: Post Exposure Prophylaxis Robert Obara, BSc MPH MBBChBAO Candidate, TCD Class of 2014 Poster for BASHIV, Dr Dominic Rowley (GMHS) et al. PEP Talk Antiretroviral drugs

More information

RECENT ADVANCES IN HIV PREVENTION & TREATMENT RESEARCH

RECENT ADVANCES IN HIV PREVENTION & TREATMENT RESEARCH RECENT ADVANCES IN HIV PREVENTION & TREATMENT RESEARCH GITA RAMJEE DIRECTOR HIV PREVENTION RESEARCH UNIT SOUTH AFRICAN MEDICAL RESEARCH COUNCIL DURBAN, SOUTH AFRICA 7 TH EDCTP FORUM BERLIN, GERMANY 30

More information

What is PrEP, or Pre-Exposure Prevention?

What is PrEP, or Pre-Exposure Prevention? What is PrEP, or Pre-Exposure Prevention? JULY 2011 What is PrEP? An HIV-negative person would use PrEP by taking certain HIV medicines daily (in either a pill or microbicide) to help him or her prevent

More information

Antiretroviral Therapy Guidelines

Antiretroviral Therapy Guidelines NORTHWEST AIDS EDUCATION AND TRAINING CENTER Antiretroviral Therapy Guidelines Christian B. Ramers, MD, MPH Medical Director, NW AETC ECHO Assistant Professor of Medicine & Global Health, University of

More information

Case Finding for Hepatitis B and Hepatitis C

Case Finding for Hepatitis B and Hepatitis C Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center

More information

Test and Treat - One component of Florida s plan to eliminate HIV transmission and reduce HIV related deaths

Test and Treat - One component of Florida s plan to eliminate HIV transmission and reduce HIV related deaths Test and Treat - One component of Florida s plan to eliminate HIV transmission and reduce HIV related deaths Medical Director, HIV/AIDS Section Division of Disease Control and Health Protection Bureau

More information

Acute Hepatitis C. Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany

Acute Hepatitis C. Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany Acute Hepatitis C Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany Conflict of Interest Honoraria for lectures and/or consultancies from abbvie, BMS, Gilead, Janssen,

More information

Prevention of Mother-to Transmission of HIV

Prevention of Mother-to Transmission of HIV Prevention of Mother-to to-child Transmission of HIV John Kinuthia MBChB, MMed,, MPH Kenyatta National Hospital/University of Nairobi 4 th INTEREST Workshop, Maputo, Mozambique Outline Burden of disease

More information